Friday 6 November 2026 Export ALKS’s income statement to Excel — free account

Alkermes plc

ALKS Healthcare Drug Manufacturers Specialty & Generic

Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024.

Revenue: +21.8%
EPS: −80.6%
Free cash flow: +6.78%

Quarter to September 2026, against a year earlier

Operating cash flow growth 3 yrs

44.61 1.28 −2.79%

Follow ALKS

Alert me

Market cap: $7.5B
P/E: 0.0×
Fwd P/E: −85.9×
Dividend yield: —
F-score: 7/9
Altman Z: 5.33
Beneish M: −3.29
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Alkermes plc (ALKS) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Alkermes plc (ALKS) trades at a P/B ratio of 4.0×. Over the past ten years it has ranged from 1.8× (March 2020) to 9.0× (December 2015); the current reading is higher than 56% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 1.8× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/ALKS/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Alkermes plc P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/ALKS/metrics/pb-ratio">Alkermes plc (ALKS) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	2.5×	(21.98%)
FY2024	3.2×	(17.92%)
FY2023	4.0×	4.71%
FY2022	3.8×	20.62%
FY2021	3.1×	13.32%
FY2020	2.8×	0.59%
FY2019	2.7×	(24.47%)
FY2018	3.6×	(44.51%)
FY2017	6.6×	0.24%
FY2016	6.5×	(27.42%)

Period	P/B ratio	Change
Sep 2026	3.6×	(24.62%)
Jun 2026	4.8×	44.23%
Mar 2026	3.4×	32.45%
Dec 2025	2.5×	(11.34%)
43 more quarters	Free account

Against its own ten years

Low 1.8× High 9.0×

Ten-year median 3.8×

Current reading's percentile 61

Company	P/B ratio
SUPN Indivior Pharmaceuticals Inc. compare	n/m
ELAN Elanco Animal Health Incorporated compare	1.8×
RDY Dr. Reddy's Laboratories Ltd compare	3.0×
ALKS Alkermes plc	4.0×
LNTH Lantheus Holdings, Inc. compare	4.9×
KNSA Kiniksa Pharmaceuticals International, plc compare	9.7×
HIMS Hims & Hers Health, Inc. compare	17.2×
LQDA Liquidia Corporation compare	20.4×
AMRX AMNEAL PHARMACEUTICALS, INC. compare	59.5×
Drug Manufacturers Specialty & Generic industry median	1.8×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Alkermes plc (ALKS) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on ALKS

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on ALKS

Stockrow Weekly